Revolution Medicines RVMD 深 沪
等待开盘 05-20 09:30:00 美东时间
144.56
+0.190
+0.13%
华盛通- 最 高146.235
- 今 开144.53
- 成交量 74.85万股
- 最 低 141.79
- 昨 收 144.37
- 总市值 307.33亿
- 52周最高 155.70
- 市盈率 静 --
- 换手率 0.35%
- 52周最低 34.00
- 委 比 -46.67%
- 总股本 2.13亿
- 历史最高 155.70
- 量 比 0.94
- 振 幅 3.08%
- 历史最低 14.08
- 每 手 1
- 风险率 34.90%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多GraniteShares Files High-Octane 2X ETFs Tied To Nuclear, AI, Biotech Momentum Stocks
GraniteShares filed for 3 new 2x ETFs tied to XE, MAIR, and RVMD, offering daily leveraged exposure to nuclear, AI, and biotech themes.
05-19 21:50
美股大行评级 | 花旗上调英特尔目标价至130美元；大摩上调英伟达目标价至285美元；National 、Yesway获多家大行首予买入评级
今日重点评级关注：TD Cowen：维持Strive"买入"评级，目标价从28美元升至30美元；蒙特利尔银行：维持KinderCare Learning"跑赢大市"评级，目标价从4美元升至6美元
05-19 10:55
美股盘后 | GLOBE LIFE涨3.24%，Fervo Energy Company Class A涨2.96%
GLOBE LIFE涨3.24%；Fervo Energy Company Class A涨2.96%；亚玛芬体育涨2.17%
05-19 06:10
Stanley Druckenmiller Dumps Amazon And Alphabet While Loading Up On Commodities, Argentina And Biotech
Stanley Druckenmiller cut Amazon, exited Alphabet while increasing bets on Argentina, commodities, semiconductors, biotech stocks during Q1.
05-18 22:12
Cancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: Report
Cancer centers race to access Revolution Medicines' pancreatic cancer drug after trial data showed survival doubled.
05-15 23:47
US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug
US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug FDA allows expanded access to Revolution Medicines' experimental pancreatic cancer drug Oncologists face logistical hurdles and resource strain to enroll patients in early access program Drug targets mutation
05-14 18:00
Erasca GAAP EPS of -$0.60
Erasca press release (ERAS): Q1 GAAP EPS of -$0.60. Cash Position: Cash, cash equivalents, and marketable securities were $408.5 million as of March 31, 2026, compared to $341.8 million as of December...
05-12 04:23
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)
Erasca and Merck collaborate on a clinical trial combining ERAS-0015, a pan-RAS molecular glue, with pembrolizumab to treat RAS-mutant solid tumors. The AURORAS-1 study aims to assess therapeutic benefits and resistance prevention. ERAS-0015 shows promising safety and efficacy in early trials.
05-11 11:00
美股大行评级 | 绩后暴跌10%，ARM仍获高盛、富国银行等多家大行上调目标价；康宁、优步、飞塔信息、西维斯、Agilon Health等获多家大行上调目标价
今日重点评级关注：Citizens：维持BioCryst制药"跑赢大市"评级，目标价从25美元升至28美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从8美元升至10美元
05-08 12:05
Needham Maintains Buy on Revolution Medicines, Lowers Price Target to $183
Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and lowers the price target from $186 to $183.
05-07 18:50
